（文章来源：证券日报） 证券日报网讯 2月25日，信邦制药在互动平台回答投资者提问时表示，公司下属的贵州医科大学附属白 云医院设立有颐康医养中心，致力为失能、半失能、术后需康复、生活难自理等人员提供全方位、专业 化、多层次、高品质的健康养老服务；公司下属的贵州医科大学附属乌当医院与本地养老院也有长期的 合作，为其提供医疗、康复及护理等服务。 ...

（编辑 袁冠琳） 证券日报网讯 2月24日，信邦制药在互动平台回答投资者提问时表示，公司从道地药材基地采购的中药 材用于自身生产中药饮片和中成药。公司已建立常用中药材战略储备机制，对冲中药材市场波动风险， 可以有效降低中药材价格异动对公司经营的影响。 ...

Core Viewpoint - The case of Wang Xiaolin, former Vice President of Guiyang Medical College, highlights significant corruption within the healthcare sector, with implications for related companies, particularly Xinbang Pharmaceutical, which is facing legal challenges due to alleged bribery [3][4][15]. Group 1: Legal Proceedings and Implications - Wang Xiaolin was sentenced to death with a two-year reprieve for accepting bribes totaling over 150 million RMB from 2002 to 2023, leveraging his positions to facilitate various business dealings [3][14]. - Xinbang Pharmaceutical is implicated in Wang's case, having received a public prosecution notice for alleged corporate bribery, which may adversely affect its profits [4][17]. - The company has acknowledged the potential negative impact of the ongoing legal proceedings on its financial performance, although it cannot yet determine the exact effects [6][17]. Group 2: Financial Performance of Xinbang Pharmaceutical - In 2024, Xinbang Pharmaceutical reported a revenue of 6.032 billion RMB, a decrease of 6.63% year-on-year, and a net profit of 101 million RMB, down 64.70% [10][21]. - For the first three quarters of 2025, the company continued to experience a decline, with revenues of 4.266 billion RMB (down 6.55%) and a net profit of 152 million RMB (down 13.74%) [10][21]. - Despite the financial downturn, Xinbang Pharmaceutical plans to distribute a cash dividend of approximately 56.89 million RMB, maintaining a dividend payout ratio of 37.35% for 2025 [11][22]. Group 3: Operational Impact and Market Position - Xinbang Pharmaceutical's subsidiary, Guizhou Keke Pharmaceutical, which is crucial to its core business, reported revenues of 2.278 billion RMB in 2023, accounting for 35.26% of the parent company's total revenue [8][19]. - The ongoing legal issues and the financial performance of its subsidiary are expected to directly influence Xinbang Pharmaceutical's overall market position and operational stability [19][21].

Group 1 - The case of Wang Xiaolin, former Vice President of Guiyang Medical College and President of its affiliated hospital, resulted in a death sentence with a two-year reprieve for bribery, along with lifelong deprivation of political rights and confiscation of personal assets [1] - The bribery scandal has implicated the A-share listed company Xinbang Pharmaceutical, which acquired 98.25% of Keke Pharmaceutical in 2013, a company formed from the restructuring of the drug sales department of the affiliated hospital [1][2] - Xinbang Pharmaceutical has grown to become a leading pharmaceutical distribution enterprise in Guizhou Province, establishing a comprehensive sales network covering major hospitals in the region [2] Group 2 - Following Wang Xiaolin's downfall, a corruption documentary aired in January 2025, revealing that a pharmaceutical supply company, restructured from the hospital's drug sales department, had terminated a merger with a state-owned enterprise under Wang's influence, leading to a subsequent acquisition by another pharmaceutical company [2]

Company Dynamics - Wang Xiaolin, former Vice President of Guiyang Medical College and President of its affiliated hospital, was sentenced to death with a two-year reprieve for bribery, with a total of over 150 million RMB received illegally from 2002 to 2023 [2] - The court found that Wang's actions had severe social impacts and warranted strict punishment, although mitigating factors such as partial restitution and confession were considered [2] Related Company Information - Xinpang Pharmaceutical, founded by alumni of Guiyang Medical College, became the first listed company in Qiannan Prefecture in 2010 and has developed into a leading pharmaceutical distribution enterprise in Guizhou Province [3] - In 2023, the subsidiary Keke Pharmaceutical reported revenues of 2.278 billion RMB and a net profit of 94.5 million RMB, accounting for 35.26% and 26.71% of Xinpang Pharmaceutical's respective figures [3] - Legal issues arose when Keke Pharmaceutical was involved in a bribery case linked to Wang Xiaolin, with the company stating that the ongoing litigation is not expected to significantly impact profits, although the exact effects remain uncertain [4]

Group 1 - The case of Wang Xiaolin, former Vice President of Guiyang Medical College, has resulted in a death sentence with a two-year reprieve for bribery, involving over 150 million RMB in illicit gains from 2002 to 2023 [2] - The bribery activities included facilitating mergers and acquisitions, procurement of medical equipment, and project contracting, which have implications for the pharmaceutical industry [2] - The involvement of Xinfang Pharmaceutical, a publicly listed company, in Wang's corruption case raises concerns about corporate governance and ethical practices within the industry [2] Group 2 - A documentary aired by Guizhou Satellite TV highlighted the influence of Wang Xiaolin in the termination of a merger with a state-owned enterprise, leading to a different acquisition that benefited him financially [3] - Legal proceedings have been initiated against Guizhou Keke Pharmaceutical Co. and individuals involved in bribery, indicating ongoing investigations into corruption within the pharmaceutical sector [3] - Xinfang Pharmaceutical has received legal notifications regarding its alleged involvement in corporate bribery, which could impact its reputation and operations [3]

Group 1 - The case of Wang Xiaolin, former Vice President of Guiyang Medical College, involves illegal acceptance of over 150 million yuan in bribes from 2002 to 2023, linked to various medical procurement and project contracts [1] - Wang Xiaolin was sentenced to death with a two-year reprieve, stripped of political rights for life, and ordered to forfeit all personal property due to the severity of his crimes [1] - The court acknowledged mitigating factors such as Wang's confession and the return of most illicit gains, leading to a lighter sentence [1] Group 2 - The corruption case has implicated A-share listed company Xinbang Pharmaceutical, which was founded in 1995 and became the first listed company in Qiannan Prefecture in 2010 [2] - Xinbang Pharmaceutical acquired a 98.25% stake in Keke Pharmaceutical in 2013, which was formed from the drug sales department of the Guiyang Medical College Affiliated Hospital, establishing a connection to Wang Xiaolin [2][3] - Keke Pharmaceutical contributed significantly to Xinbang Pharmaceutical's financials in 2023, accounting for 35.26% of revenue and 34.75% of net assets [3] Group 3 - The corruption chain involved Wang Xiaolin's influence in halting a merger with a state-owned enterprise, leading to Keke Pharmaceutical being acquired by Xinbang Pharmaceutical instead, resulting in substantial bribes exchanged [3] - Legal proceedings against Xinbang Pharmaceutical began in 2025, with the company announcing that the ongoing litigation would not significantly impact its current or future profits, although the exact effects remain uncertain [4][5] - The company has received formal charges from the prosecutor's office regarding the alleged bribery, indicating ongoing legal challenges [5]

Core Viewpoint - The company has signed a guarantee contract with China Everbright Bank for a total guarantee amount of 40 million RMB for its subsidiary [2] Group 1 - The company announced on February 4 that it signed a guarantee contract with China Everbright Bank's Guiyang branch on February 3, 2026 [2] - The guarantee is for a comprehensive credit application made by its subsidiary, Guizhou Tongde Pharmaceutical Co., Ltd. [2] - Mr. Wang Wenyuan provided a counter-guarantee to the company and signed a counter-guarantee contract on the same day [2]

证券代码：002390 证券简称：信邦制药 公告编号：2026-004 贵州信邦制药股份有限公司 关于为控股子公司提供担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、担保事项审批情况 贵州信邦制药股份有限公司（以下简称"公司"）于 2025 年 4 月 11 日召开的第九届董事会第六次会议审议通过了《关于 2025 年度 向银行申请授信及担保事项的议案》，董事会同意 2025 年度公司及 合并报表范围内子公司（以下简称"子公司"）向银行申请总额不超 过 210,000 万元的银行综合授信，公司为子公司提供担保额度不超过 170,000 万元，其中为资产负债率低于 70%的子公司提供担保的额度 不超过 120,000 万元，为资产负债率 70%以上的子公司提供担保的额 度不超过 50,000 万元。详情可参见 2025 年 4 月 15 日刊登于中国证 券报、证券时报及巨潮资讯网（http://www.cninfo.com.cn）的《关 于公司 2025 年度向银行申请授信及担保事项的公告》（公告编号： 2025-011）。上述事项已于 2025 ...

Core Viewpoint - Xinbang Pharmaceutical (002390) announced on January 26 that it needs to pay back taxes and late fees totaling 50.7869 million yuan, which will directly impact its annual profit for 2025 [1] Group 1: Financial Impact - The company itself is responsible for 2.6957 million yuan of the tax and late fees, while its subsidiaries account for 48.0912 million yuan [1] - This expenditure will be recorded in the profit and loss statement for the year 2025, indicating a significant financial burden [1] Group 2: Legal Issues - Earlier in January, the company received a prosecution notice from the People's Procuratorate of Kaiyang County, Guizhou Province, regarding allegations of corporate bribery [1]